Descriptor English: | Palivizumab | ||||
Descriptor Spanish: |
Palivizumab
| ||||
Descriptor Portuguese: | Palivizumab | ||||
Descriptor French: | Palivizumab | ||||
Entry term(s): |
MEDI 493 MEDI-493 MEDI493 Monoclonal Antibody MEDI 493 Monoclonal Antibody MEDI-493 Monoclonal Antibody MEDI493 Synagis |
||||
Tree number(s): |
D12.776.124.486.485.114.224.060.860 D12.776.124.790.651.114.224.060.860 D12.776.377.715.548.114.224.200.860 |
||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000069455 | ||||
Scope note: | A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients. |
||||
Allowable Qualifiers: |
AD administration & dosage AE adverse effects AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification DE drug effects EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects TO toxicity TU therapeutic use UL ultrastructure UR urine |
||||
Pharm Action: |
Antiviral Agents |
||||
Registry Number: | DQ448MW7KS | ||||
Public MeSH Note: | 2016; PALIVIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 1998-2015 |
||||
History Note: | 2016 (1998) |
||||
DeCS ID: | 55978 | ||||
Unique ID: | D000069455 | ||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||
Date Established: | 2016/01/01 | ||||
Date of Entry: | 2015/07/01 | ||||
Revision Date: | 2017/04/10 |
-
-
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Palivizumab
- Preferred
MEDI 493
- Narrower
Synagis
- Narrower
Concept UI |
M0288015 |
Scope note | A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients. |
Preferred term | Palivizumab |
Concept UI |
M0288016 |
Preferred term | MEDI 493 |
Entry term(s) |
MEDI-493 MEDI493 Monoclonal Antibody MEDI 493 Monoclonal Antibody MEDI-493 Monoclonal Antibody MEDI493 |
Concept UI |
M0358707 |
Preferred term | Synagis |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey